11 Up and Coming Stocks To Watch

The stock market changes by the minute. What looks like a terrible investment can look like a terrific opportunity within minutes.

You can’t keep track of every company that might make a move in the near future. You can, however, use this list of up and coming stocks to watch. Depending on the companies’ decisions, you could turn a little knowledge into a chance to earn thousands in the market.

The following stocks to watch for show promise but as always with companies that are under the radar, risk is higher than a bellwether with dominant market share. Still, these are the stocks that could pop when you least expect it.

10,000+ Clients Trust Verint Systems 

Verint Systems (VRNT) develops hardware and software focused on analyzing large data sets. Their products have features for improving security, business intelligence, and surveillance.

They also make customer engagement and management solutions that help companies identify potential sales.

More than 10,000 organizations in 180 countries around the world rely on Verint’s technology, so its highly diversified customer base insulates it from the shock of losing even a good chunk of its base should economic clouds form.

Verint Systems makes the list of up and coming stocks to watch because its valuation using discounted cash flow forecasting shows upside of over 40% and it is making a strong return from the mid-March crash.

In early 2020, Verint Shares were about $60 each. They fell to about $34 on March 16. Since then, the stock value has been returning to normal. Should the value return to $60, it makes sense to buy shares now.

Akebia Therapeutics > Focus On Kidney Treatments

Akebia Therapeutics is on a mission to prevent and treat kidney disease. The company has been researching and testing medications since 2007.

So far, it has one drug, AURYXIA, that helps patients with kidney disease maintain healthy iron and phosphorus levels.

The medication has different applications depending on whether the patient is on dialysis.

Akebia Therapeutics (AKBA) makes this list because it recently released results from phase three tests of its Vadadustat, a drug designed to treat anemia in adult patients with chronic kidney disease.

The positive results show that Akebia is one step closer to releasing a new drug that could increase its revenues.

Akebia also stands out because of its low share price. You can buy shares for less than $3. The stock’s highest price occurred in 2014 when it reached $30. If the drug treatment gets approval, Akebia stock prices may potentially rise ten-fold.

Veritiv Keeps Work Environments Hygienic

Unless you own a business, you probably haven’t heard much about Veritiv Corporation (VRTV).

The B2B supplier primarily sells shipping products to large companies. With the vast majority of companies needing shipping and packing supplies, you can expect Veritiv to keep earning money.

Pay attention to Veritiv for a different reason, though. It sells cleaning products for offices, factories, and other facilities.

As more businesses realize that coronavirus will remain a problem for the foreseeable future, they have started spending more on the products that they need to disinfect work environments.

Veritiv can also supply personal protection items, including gloves and masks that help keep employees safe at work.

During early September, Vertitiv shares cost about $20. That makes it a fairly low-risk investment, especially when you consider a classic cash flow analysis shows upside north of 25%. Could this up and coming stock turn into a serious moneymaker?

Atara Biotherapeutics Needs FDA Approval To Pop

Atara Biotherapeutics (ATRA) develops T-cell immunotherapy products for patients living with cancer, viral, and autoimmune disease. Atara has at least two treatments in Phase 3 testing. Two others are in Phase 1 trials.

Perhaps most impressive, though, are the six drugs in preclinical trials. It may take several years for these products to reach the market, but they could push Atara’s stock price much higher.

In 2018, shares in Atara surpassed $50. Since then, the slow process of drug approval has made a lot of people lose interest in the company.

Once Atara’s products reach the market, the company can start earning revenues. Most importantly, keep an eye on the upcoming trials for Atara’s proposed treatments. As they move through the phases and get closer to FDA approval, you may see the company’s stock prices grow quickly.

Sierra Wireless Is Tethered To The 5G Revolution

Communication technology evolves rapidly. If individuals and companies want to work more efficiently, then they need tools that will unlock the value of 5G, cloud solutions, networking solutions, and other pieces of software and hardware. 

Sierra Wireless (SWIR) stands at the cutting edge of developing new communications technology.

So far, the company has found ways to use its technology to improve industrial manufacturing, public safety, energy and natural resources, transportation, and logistics.

Why is Sierra Wireless one of the top stocks to watch for the future? Two reasons stand out.

(1) Many companies have just started rolling out there 5G towers and mobile phones. Sierra Wireless already has a head start that could make it an industry leader.

(2)Sierra Wireless’s stock prices are close to rock bottom. With a fair value almost 20% higher, this stock has upside potential for patient investors.

Will Compugen See An Autoimmune Breakthrough?

Compugen (CGEN) collaborates with some of the world’s best-known medical companies, including Bayer and Bristol-Myers Squibb.

The company developed these relationships early in its career by providing support services. Eventually, Compugen decided to start developing its own drugs. It focuses on making treatments for autoimmune diseases and immuno-oncology.

Compugen is running several clinical trials. It has also released some products that help healthcare professionals to improve treatment options for immuno-oncology and autoimmune diseases. It’s worth noting that medical researchers still have a lot to learn about autoimmune diseases. 

Compugen’s recent discoveries and clinical trials have already caught the attention of investors. In 2018, investors could buy shares for as little as $2.50. The share price peaked two years later, over the summer, when it reached $18.93.

There are no guarantees that Compugen will reach its goals. If it does, then you can expect to see stock prices climb quickly. Analysts are expecting it to do so with a price target 30% higher than where CGEN share price sat most recently.

INOVIO Pharmaceuticals Didn’t Drop When Covid Hit

Something amazing happened to INOVIO Pharmaceuticals (INO) mid-March, when fear of coronavirus pushed most stock prices much lower than anticipated. INOVIO barely budged.

In fact, shares reached their maximum value in five years on June 26, 2020, when it nearly broke $30. You have to go back 20 years to see the company’s stock perform better than that.

Why did INOVIO Pharmaceuticals (INO) suddenly become one of the up and coming stocks to invest in?

Largely because it started devoted so many of its resources to develop a COVID-19 DNA vaccine. The company has already released numerous treatments for improving immunity, stopping infection disease, and treating HPV-associated diseases.

Of course, plenty of companies are working around the clock to make a COVID-19 vaccine. What makes INOVIO such a good buy?

An intrinsic value over 40% higher than where shares sat most recently is a bullish sign for long-term investors.

Will Teck Resources Rise With Gold?

Teck Resources (TECK) develops innovative ways to capture natural resources, including precious metals and energy. The company casts a wide net by refusing to focus on a single resource. At any given time, Teck Resources is looking for major extractions of coal, zinc, copper, and oil.

Teck isn’t one of those natural resource companies that think the planet can provide riches forever. In 2020, it announced an agreement to purchase a company that had already done exemplary work in capturing solar power.

Right now, the vast majority of its money comes from non-renewal resources. It’s good to see that it understands the importance of planning for the future, though.

Keep in mind, though, that Teck Resources doesn’t have a great track record for environmentalism. Some critics worry that the company’s investment in renewable energies is a smokescreen to distract investors and regulators.

Looking at a five-year chart, you can see how various controversies influenced the company’s stock prices. Not surprisingly, the value fell quickly in March. It has excellent work regaining its value, though.

As long as Tech Resources avoids controversies and shows a commitment to renewable energies, it seems likely that it’s stock prices will climb. This is a long-term investment, though. Don’t expect the price to change overnight.

Babywear Is Always In Demand So Buy Carter’s?

Carter’s (CRI) has been making merchandise for children since 1865. It started by making children’s clothing under brand names like Carter’s and OshKosh B’Gosh.

In recent years, the company has expanded to e-commerce, which makes it easier for customers to explore their options and order online instead of traveling to a traditional brick-and-mortar store.

A great thing about Carter’s is that it refused to pigeon-hole itself by exclusively making its own products. It formed alliances with major retailers like Target, Walmart, and Amazon.

Each company got the same high-quality products, but they have unique brands that help Carter’s to reach a wider range of consumers.

Carter’s has a history of success that stretches back more than 150 years. Why add them to a list of up and coming stocks to invest in, now?

As if often the case these days, the answer lies with coronavirus. On February 21, Carter’s stock sold for over $110. Over March, share prices plummeted to about $65. Many people lost nearly half of the money invested in Carter’s.

The March dip created a lot of opportunities for investors. In fits and jerks, the stock has reached $90 a few times. A sharp valley followed each peak.

New investors who pay close attention to the peaks and valleys may find that they can get a reliable stock at an extremely reasonable rate.

When the economy recovers and consumers feel more comfortable dressing their children in high-quality, adorable clothing, who knows how high Carter’s stock prices could go?

SLM Corporation aka Sallie Mae

SLM Corporation (SLM), which you probably know as Sallie Mae, provides financial services to students.

If you had to borrow money to attend college, then you certainly know Sallie Mae’s name. You may even owe the company money.

Have no doubt: the recession has hurt SLM Corporation recently. In March, when people started worrying about losing their jobs, many of them reached out to their loan processors to request extensions. In the mind of an adult, you have to prioritize your mortgage or rent over student loans.

Unfortunately, for Sallie Mae, it’s stock prices haven’t rebounded. It bottomed out near $6 on April 3. Since then, it has barely broken the $8 mark. The reason seems obvious. People still worry about their financial futures. Investors know that, and they’re not completely convinced that Sallie Mae’s borrowers will repay all of their money.

Right now, you probably wonder how SLM Corporation can make it on a list of up and coming stocks to invest in. The answer is relatively easy, though.

Over the last 40 years, SLM Corp’s stock value peaked at $25.57. That’s not a lot of money, but it’s about five times the stock’s value now if you time your purchase right.

No one knows where Sallie Mae will head. The extremely low barrier to invest, though, makes it tempting. 

Up And Coming Stocks To Watch Final Thoughts

Technology, healthcare, and retail companies make for interesting investing prospects. Of course, the ways that company stocks move depend on a long list of factors. If a medical company makes a COVID-19 vaccine, will it get rushed to the market? Will the company make much money off of the vaccine, or will insurance companies argue that government subsidies already paid for the development?

Everything from the unemployment rate to how governments respond to COVID numbers will affect these and other stocks.

You know that the stock market can never give you a guarantee. At the same time, you know that some companies will perform better than others. How will you pick the winners over the losers?

Start by making a list of stocks to invest in. Then, pay close attention to how those companies perform. Do your research by reading clinical trials and press releases.

The more you know about stocks on the edge of breaking big, the more information you have when deciding which shares to buy.

---

The author has no position in any of the stocks mentioned. Financhill has a disclosure policy. This post may contain affiliate links or links from our sponsors.